Cited by 242Barrier Structure and Function StudiesAlzheimer's disease research and treatmentsDrug Transport and Resistance Mechanisms

Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer.

Open access
Mackic, J B, Stins, M, McComb, J G, Calero, M, Ghiso, J, Kim, K S, Yan, S D, Stern, D +3 more·1998·Journal of Clinical Investigation

Abstract

A soluble monomeric form of Alzheimer's amyloid-beta (1-40) peptide (sAbeta1-40) is present in the circulation and could contribute to neurotoxicity if it crosses the brain capillary endothelium, which comprises the blood-brain barrier (BBB) in vivo. This study characterizes endothelial binding and transcytosis of a synthetic peptide homologous to human sAbeta1-40 using an in vitro model of human BBB. 125I-sAbeta1-40 binding to the brain microvascular endothelial cell monolayer was time dependent, polarized to the apical side, and saturable with high- and low-affinity dissociation constants of 7.8+/-1.2 and 52.8+/-6.2 nM, respectively. Binding of 125I-sAbeta1-40 was inhibited by anti-RAGE (receptor for advanced glycation end products) antibody (63%) and by acetylated low density lipoproteins (33%). Consistent with these data, transfected cultured cells overexpressing RAGE or macrophage scavenger receptor (SR), type A, displayed binding and internalization of 125I-sAbeta1-40. The internalized peptide remains intact > 94%. Transcytosis of 125I-sAbeta1-40 was time and temperature dependent, asymmetrical from the apical to basolateral side, saturable with a Michaelis constant of 45+/-9 nM, and partially sensitive to RAGE blockade (36%) but not to SR blockade. We conclude that RAGE and SR mediate binding of sAbeta1-40 at the apical side of human BBB, and that RAGE is also involved in sAbeta1-40 transcytosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci2029

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Mackic, J. B., Stins, M., McComb, J. G., Calero, M., Ghiso, J., Kim, K. S., Yan, S. D., Stern, D., Schmidt, A. M., Frangione, B., & Zlokovic, B. V.
Affiliations
  • University of Southern California (US)
  • NYU Langone Health (US)
  • Columbia University (US)
Venue
Journal of Clinical Investigation
Published
1998-08-15
Volume
102
Issue
4
Pages
734-743
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2150611166
Cited by
242
References
51
Citations by year
2026: 3 · 2025: 4 · 2024: 2 · 2023: 9 · 2022: 6 · 2021: 7 · 2020: 4 · 2019: 10 · 2018: 5 · 2017: 9 · 2016: 9 · 2015: 14 · 2014: 2 · 2013: 6 · 2012: 15
FWCI
6.22
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • KU ScholarWorks (University of Kansas) (submittedVersion, other-oa)
Funders
  • American Heart Association
  • National Institutes of Health (1r03ag014526-01)
  • National Institute on Aging (AG-14526, AG05891)
  • National Institute of Neurological Disorders and Stroke (NS34467)
Topics
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
Aβ40, blood-brain barrier, RAGE, receptor for advanced glycation end products, transcytosis, endocytosis, brain microvascular endothelial cells, receptor binding, acetylated low density lipoprotein, Alzheimer's disease, peptide internalization
MeSH terms
Receptor for Advanced Glycation End Products, Alzheimer Disease, Amino Acid Sequence, Biological Transport, Blood-Brain Barrier, Endocytosis, Endothelium, Vascular, Humans, Membrane Proteins, Microcirculation, Molecular Sequence Data, Peptide Fragments, Receptors, Immunologic, Recombinant Proteins, Amyloid beta-Peptides, Cell Polarity, Receptors, Lipoprotein, Receptors, Scavenger, Scavenger Receptors, Class A, Scavenger Receptors, Class B

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review